PlantEXT has entered into a license agreement with The Government of the State of Israel and has funded research at ARO thus acquiring the exclusive global rights to commercialize ARO’s intellectual property (“IP”) and products based on formulations of active cannabis compounds and possibly other pharmaceutical drugs as a basis for development of products for the treatment of lung inflammation such as the inflammation provoked by COVID-19. (pending final government approval)
Preliminary research results have identified cannabis fractions and compounds that cause anti-inflammatory activity in lung epithelial cell line and macrophages in 2D in vitro cultures using different associated markers, those associated with COVID inflammation and those characterize asthma inflammation.
2300 Yonge Street, Suite 1709
Toronto, ON
M4P 1E4
Developing and commercializing the most effective, clinically evidenced medical cannabis formulations that improve the quality of life for patients across the globe.
